Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Codexis, Inc.
Type
Public
Traded as NASDAQ: CDXS
Industry protein engineering, biocatalysis, pharmaceuticals, biotherapeutics, industrial biotechnology, fine chemicals
Founded 2002
Headquarters Redwood City, CA, U.S.,
Key people
  • John J. Nicols (CEO and President)
  • Jim Lalonde (Vice President Research and Development)
  • Gordon Sangster (CFO)
Revenue Increase US$33-35 million (FY 2013)
Number of employees
88 (as of April 2014)
Website Codexis, Inc.

Codexis, Inc. is a leading protein engineering company that applies its revolutionary CodeEvolver platform technology to deliver high-performing enzymes for improving the cost and quality of pharmaceuticals and food ingredients, to enable sequencing of minute quantities of DNA for medical diagnostics, and to create novel biotherapeutics.

Codexis engineers custom enzymes and microorganisms, which are sometimes referred to as biocatalysts. Codexis' proprietary technology called CodeEvolver is directed evolution technology based on the concept that natural genetic mutation and selection can be accelerated in the research laboratory to obtain specific improvements in the function of single proteins and multiprotein pathways. CodeEvolver combines DNA shuffling and bioinformatics with systems biology to create new biocatalysts.

Codexis is using its work in biofuels to develop sustainable sources for the 2 million ton detergent alcohol market. Detergent alcohols go into household products such as shampoo and conditioner. Approximately 70% of detergent alcohols are derived from palm kernel oil. The remaining 30% is derived from petroleum. The rising price and price volatility of palm oil and crude oil combined with environmental concerns have prompted consumer product companies to seek out sustainable alternatives.

Codexis supplies varying quantities of its enzymes to pharmaceutical companies, from small to moderate quantities while they are optimizing their production processes, to larger quantities during later-stage clinical development and commercial scale drug production. Codexis also provides enzyme optimization services.

Customers can send Codexis their materials to test against Codexis’ existing libraries of enzymes. If Codexis detects desired activity in a specific enzyme, it can supply the customer with this enzyme or perform optimization services to improve the performance of the enzyme.

Codexis is based in Redwood City, CA and was incorporated in 2002. The company went public in April 2010 on NASDAQ.

Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor and a second time with Merck in 2010 for its work on the active ingredient in Januvia.

Investment goal date:
Dividends reinvested
Codexis, Inc. CDXS report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-08
--
--
Q4 2017
2018-03-07
--
--
Q4 2017
2018-03-05
--
--
Q3 2017
2017-11-09
-0.2100
0.0000
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-09
-0.1300
-0.1300
Q1 2017
2017-05-09
-0.1800
-0.1800
Q4 2016
2017-03-09
-0.1300
-0.1300
Q3 2016
2016-11-08
0.0300
0.0300
Q2 2016
2016-08-09
0.0500
0.0500
Q1 2016
2016-05-09
-0.1700
-0.1700
Q4 2015
2016-03-03
-0.0500
-0.0500
Q3 2015
2015-11-04
0.1300
0.1300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BAILLIE GIFFORD & CO
1185133
BlackRock Fund Advisors
1107455
BlackRock Inc.
2448636
BlackRock Institutional Trust Company, N.A.
1237656
BRIDGEWAY CAPITAL MANAGEMENT INC
270700
FMR LLC
1274759
GEODE CAPITAL MANAGEMENT, LLC
226644
Nantahala Capital Management, LLC
5998322
NORTHERN TRUST CORP
352224
Opaleye Management Inc.
1170000
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
288275
RENAISSANCE TECHNOLOGIES LLC
794600
STATE STREET CORP
457866
Vanguard Group, Inc
1074171
ZACKS INVESTMENT MANAGEMENT
322647
Major Shareholders
Name Relationship
Total Shares
Holding stocks
BARUCH THOMAS R
0.5000% (197170)
CDXS / IMI /
MAXYGEN INC
1.3400% (524643)
CDXS /
SHAW ALAN
0.5200% (202000)
CDXS /
KELLEY BERNARD J
0.6100% (240157)
CDXS /
WOLF DENNIS P
0.3600% (141254)
CDXS / FIO / QTM /
Smith David V
0.1600% (62679)
CDXS / OGXI /
NICOLS JOHN J
2.9800% (1164854)
CDXS /
SANGSTER GORDON
0.4900% (190422)
CDXS /
Yang Patrick Y
0.8600% (338234)
AMRS / CDXS / CLDN / TSO /
Pasternack Bruce A
0.0300% (10000)
ACCL / CDXS /
Strumph Peter M
0.1600% (60756)
CDXS /
Karsner Alexander
0.2000% (78519)
AMAT / CDXS /
Lawson Robert J
0.1100% (44000)
CDXS /
Anton David L.
0.2400% (93777)
CDXS /
Sarret Joseph J.
0.1900% (74000)
CDXS /
Sheehy Douglas T.
0.6300% (247617)
CDXS /
Equilon Enterprises LLC
14.2400% (5573319)
CDXS /
O'Toole David D
0.2800% (110687)
CAPN / CDXS / MNOV / RGDX /
Vivo Ventures Fund VII, L.P.
0.2300% (90330)
CDXS /
Dorgan Byron L
0.5000% (194670)
CDXS /
Ispagnac Participacoes Ltda.
14.2400% (5573319)
CDXS /
Shell Brazil Holding B.V.
14.2400% (5573319)
CDXS /
Dowd Brian Paul
0.0700% (28310)
CDXS /
Tobin Matthew
0.2000% (78707)
CDXS /
VIVO VENTURES VII, LLC
0.2900% (115321)
CDXS / MEIP /
Seufer-Wasserthal Peter
0.2400% (93064)
CDXS /
Lalonde James
0.6200% (241986)
CDXS /
Glaub Kathleen Sereda
0.2600% (102197)
CDXS /
% ()